Ocular Therapeutix will unveil topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet age-related macular degeneration, via webcast on February 17, with fuller data slated for the Macula Society meeting later in the month. AXPAXLI is an intravitreal axitinib formulated in a bioresorbable hydrogel designed for sustained retinal delivery. The program sits alongside ongoing Phase 3 work in diabetic retinal disease, while the company’s commercial anchor remains DEXTENZA in post‑operative ocular inflammation and allergic conjunctivitis.
A superiority design in wet AMD is a bold swing. If AXPAXLI can outperform today’s standards—dominated by extended-interval anti-VEGF regimens—it could reset expectations for durability, visit burden, and outcomes in a market that has evolved yet remains constrained by frequent injections and adherence friction. The strategic question is whether a tyrosine kinase inhibitor delivered via hydrogel can achieve clinically meaningful superiority without compromising ocular safety, and whether that advantage is large enough to change payer behavior and clinic workflows.
This matters now because the retina market is in the midst of a durability arms race. High-dose aflibercept has lengthened intervals, faricimab has carved share with dual-pathway biology, and device-based sustained delivery has re-emerged after earlier setbacks. Yet many patients still require monthly or bi‑monthly injections, adherence is imperfect, and real-world outcomes often trail trials. A successful hydrogel-based, small-molecule inhibitor could offer multi-month disease control with fewer clinic visits, directly addressing capacity constraints in retina practices. For patients, that means less treatment fatigue; for HCPs, smoother scheduling and potentially fewer rescue injections; for payers, a chance to trade procedure volume for durable control—if the evidence supports it and pricing aligns with reduced utilization.
The bar is high. Long-acting candidates in wet AMD have delivered mixed readouts over the past several years, and intravitreal TKIs have raised safety considerations ranging from inflammation to particle behavior. AXPAXLI’s bioresorbable hydrogel is a differentiator that may mitigate some risks while enabling sustained elution, but the data will need to demonstrate a clean intraocular safety profile alongside superiority on visual acuity and anatomic endpoints, as well as meaningful reductions in treatment burden and rescue rates. Anything short of a compelling combined efficacy‑durability‑safety package risks getting lost amid entrenched brands, emerging biosimilars, and increasingly prescriptive step‑through policies.
Commercially, a win would stretch Ocular beyond its current perioperative footprint into the high-stakes buy‑and‑bill retina channel. That requires field scale-up, distribution alignment, reimbursement pull‑through, and Medical Affairs mobilization around mechanism, patient selection, dosing paradigms, and real-world evidence to validate durability claims. It also reframes the company’s partnering optionality. Positive superiority data could draw interest from ophthalmology incumbents consolidating retina portfolios or seeking assets that reduce clinic burden—a central theme in recent BD activity—while ex‑US alliances could accelerate access in markets where injection frequency drives resource strain.
What to watch on February 17 is simple and unforgiving: the primary endpoint and effect size; durability metrics such as injection-free intervals and rescue rates; consistency across subgroups; and a crisp safety readout, particularly intraocular inflammation and pressure signals. The follow-on question is whether the dataset is strong enough to influence payer criteria and clinical algorithms in the near term, or whether it sets the stage for confirmatory evidence and head‑to‑head positioning against high-dose aflibercept and faricimab. If SOL-1 delivers clear superiority with clean safety, the next competitive reshuffle in retina could begin immediately; if it does not, the window for new long-acting modalities in wet AMD may narrow faster than anticipated.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
